Sarah Pringle

Blackstone invests in Cryoport causing the latter's stock to soar and Levine Leichtman acquires BigHand from Bridgepoint Development.

For Blackstone, investing in Cryoport offers a means to ride the rapid and sustained growth of cell and gene therapy without taking on direct idiosyncratic risk. 

Concluding an Edgemont Partners sale process, the European suitor emerges with a deal that leaves management with an approximately 20% stake in the medical device services company.

Blackstone Tactical Opportunities will be investing $275 million in Cryoport to support two new acquisitions in the cell and gene therapy supply chain.

Erlanger Health System rebuffs StoneBridge's $425 million bid to acquire Erlanger Health Systems and Venn Growth expands its team while preparing to roll out a $300 million inaugural fund.

If passed, SB 977 would give the California attorney general never-before-seen authority over healthcare consolidation, but not every buyer is included and there could be ways for PE firms to circumvent the law, lawyers said.

Warburg Pincus-backed Qualifacts unites with Martis Capital’s Credible Behavioral Health in healthcare tech merger and Clearlake's TEAM Technologies acquires Baril Corp.

Warburg’s September investment in Qualifacts valued the behavioral health software-as-a-service company at close to $350 million, sources told PE Hub at the time. 

Takeda Pharmaceutical is divesting its Japanese consumer healthcare business to Blackstone Group and Branford Castle Partners buys Fibrix Filtration.

Swiss PE giant Partners Group will retain a minority investment in the pharma services company.